Ticker Details
Neurocrine Biosciences, Inc. Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.
IPO Date:	May 23, 1996
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$13.21B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.86 | 1.94%
Avg Daily Range (30 D):	$1.44 | 1.11%
Avg Daily Range (90 D):	$1.68 | 1.23%

Institutional Daily Volume
Avg Daily Volume:	.69M
Avg Daily Volume (30 D):	.78M
Avg Daily Volume (90 D):	.86M

Trade Size
Avg Trade Size (Sh.):	91
Avg Trade Size (Sh.) (30 D):	43
Avg Trade Size (Sh.) (90 D):	44

Institutional Trades
Total Institutional Trades:	12,214
Avg Institutional Trade:	$4M
Avg Institutional Trade (30 D):	$10.75M
Avg Institutional Trade (90 D):	$11.05M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$9.46M
Avg Closing Trade (30 D):	$27.37M
Avg Closing Trade (90 D):	$25.34M
Avg Closing Volume:	100.12K

News

Apr 6, 2026 @ 8:20 PM Why Soleno Therapeutics Stock Rocketed Higher on M... Source: Eric Volkman

Apr 6, 2026 @ 12:13 PM Neurocrine Buys Soleno To Tap High-Growth Rare Dis... Source: Vandana Singh

Mar 23, 2026 @ 5:17 PM Biohaven Stock Down 70% but One Fund's New $6 Mill... Source: Jonathan Ponciano

Feb 12, 2026 @ 7:38 PM Analysts Stay Bullish As Neurocrine Shares Tumble ... Source: Vandana Singh

Dec 23, 2025 @ 1:14 PM Clinical Miss For Neurocrine's Cerebral Palsy Drug... Source: Vandana Singh

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$4.81	$1.54	$4.81
Diluted EPS	$4.67	$1.48	$4.67
Revenue	$2.86B	$805.5M	$2.86B
Gross Profit	$2.81B	$787.9M	$2.81B
Net Income / Loss	$478.6M	$153.7M	$478.6M
Operating Income / Loss	$619.1M	$210.9M	$619.1M
Cost of Revenue	$52.1M	$17.6M	$52.1M
Net Cash Flow	$480M	$372.8M	$480M
PE Ratio	27.60